One exceptional case is cerliponase alfa (BrineuraTM), a recombinant proenzyme form of human tripeptidyl peptidase-1 (TPP1) approved for treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease via intraventricular infusion [223]. This evidence concerns the gene TPP1 and neuronal ceroid lipofuscinosis 2.